Esperion Therapeutics Inc. (NASDAQ: ESPR) kicked off on Friday, up 4.23% from the previous trading day, before settling in for the closing price of $1.89. Over the past 52 weeks, ESPR has traded in a range of $0.70-$3.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 7.64% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 88.01%. With a float of $194.16 million, this company’s outstanding shares have now reached $196.22 million.
In an organization with 240 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 81.81%, operating margin of 1.78%, and the pretax margin is -35.46%.
Esperion Therapeutics Inc. (ESPR) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Esperion Therapeutics Inc. is 1.05%, while institutional ownership is 72.26%. The most recent insider transaction that took place on Sep 17 ’24, was worth 26,132. In this transaction President and CEO of this company sold 14,550 shares at a rate of $1.80, taking the stock ownership to the 752,266 shares. Before that another transaction happened on Sep 17 ’24, when Company’s Chief Commercial Officer sold 2,608 for $1.78, making the entire transaction worth $4,650. This insider now owns 162,659 shares in total.
Esperion Therapeutics Inc. (ESPR) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 88.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.90% during the next five years compared to 23.09% growth over the previous five years of trading.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Trading Performance Indicators
Take a look at Esperion Therapeutics Inc.’s (ESPR) current performance indicators. Last quarter, stock had a quick ratio of 1.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.88, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach 0.17 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc. (ESPR)
Let’s dig in a bit further. During the last 5-days, its volume was 3.13 million. That was inferior than the volume of 6.41 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 57.41%. Additionally, its Average True Range was 0.13.
During the past 100 days, Esperion Therapeutics Inc.’s (ESPR) raw stochastic average was set at 25.32%, which indicates a significant decrease from 63.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.99% in the past 14 days, which was higher than the 73.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8232, while its 200-day Moving Average is $2.2600. However, in the short run, Esperion Therapeutics Inc.’s stock first resistance to watch stands at $2.0067. Second resistance stands at $2.0433. The third major resistance level sits at $2.1067. If the price goes on to break the first support level at $1.9067, it is likely to go to the next support level at $1.8433. Assuming the price breaks the second support level, the third support level stands at $1.8067.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Key Stats
The company with the Market Capitalisation of 386.55 million has total of 189,460K Shares Outstanding. Its annual sales at the moment are 116,330 K in contrast with the sum of -209,250 K annual income. Company’s last quarter sales were recorded 73,830 K and last quarter income was -61,930 K.
